Li Ni, Tan Fengwei, Chen Wanqing, Dai Min, Wang Fei, Shen Sipeng, Tang Wei, Li Jiang, Yu Yiwen, Cao Wei, Xu Yongjie, Qin Chao, Zhao Liang, Zhu Meng, Guo Lanwei, Wu Zheng, Yang Zhuoyu, Zheng Yadi, Chen Hongda, Liu Yunyong, Wei Donghua, Dong Dong, Cao Ji, Zhang Shaokai, Yan Shipeng, Wang Ning, Du Lingbin, Shen Hongbing, Wu Ning, He Jie
Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Key Laboratory of Cancer Data Science, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Lancet Respir Med. 2022 Apr;10(4):378-391. doi: 10.1016/S2213-2600(21)00560-9. Epub 2022 Mar 8.
Lung cancer is the leading cause of cancer death worldwide. Data on the effectiveness of one-off low-dose CT (LDCT) in reducing lung cancer mortality and all-cause mortality are needed to inform screening programmes in countries with limited medical resources. We aimed to evaluate the effectiveness of one-off LDCT screening in the early detection of lung cancer in China.
A multicentre, population-based, prospective cohort study was done in 12 cities of eight provinces across China, recruiting individuals aged 40-74 years who were asymptomatic for lung cancer with no lung cancer history. Participants were classified as at high risk or low risk of lung cancer using a sex-specific risk score that incorporated cigarette smoking, level of physical activity, occupational exposures, history of chronic respiratory diseases, family history of lung cancer, diet, and passive smoking (women only). Participants at high risk were invited for a one-off LDCT scan and were classified into screened and non-screened groups on the basis of whether or not they had the scan. Lung cancer incidence density, lung cancer mortality, and all-cause mortality were calculated for the screened and non-screened groups. The effectiveness of a one-off LDCT scan was evaluated by a comparison of the screened and non-screened groups in terms of lung cancer mortality and all-cause mortality in the period from cohort entry until administrative censoring (June 20, 2020). Inverse probability weighting was adopted to account for potential imbalanced factors between the two groups and Cox proportional hazards model was used to estimate the weighted associations between mortality and one-off LDCT scans.
Between Feb 19, 2013, and Oct 31, 2018, 1 032 639 individuals were assessed for eligibility. 1 016 740 participants were enrolled in the study, of whom 3581 had a lung cancer diagnosis after a median follow-up of 3·6 years (IQR 2·8-5·1). Among the 223 302 participants at high risk, 79 581 (35·6%) had an LDCT scan (screened group) and 143 721 (64·4%) did not (non-screened group). After inverse probability weighting, lung cancer incidence density was 47·0% higher (hazard ratio 1·47 [95% CI 1·27-1·70]; p<0·0001), lung cancer mortality was 31·0% lower (0·69 [95% CI 0·53-0·92]; p=0·010) and all-cause mortality was 32·0% lower (0·68 [0·57-0·82]; p<0·0001) for participants in the screened group compared with those in the non-screened group.
One-off LDCT screening was associated with significantly lower lung cancer mortality and all-cause mortality in a large population in China. Our results point to the promise of one-off LDCT screening in countries with limited medical resources. Further studies are needed to explore interactions by subgroup-including sex, age, smoking status, and economic status-to develop population-specific screening strategies.
Ministry of Finance and National Health Commission of the People's Republic of China.
For the Chinese translation of the abstract see Supplementary Materials section.
肺癌是全球癌症死亡的主要原因。在医疗资源有限的国家,需要有关一次性低剂量CT(LDCT)在降低肺癌死亡率和全因死亡率方面有效性的数据,以指导筛查计划。我们旨在评估一次性LDCT筛查在中国早期发现肺癌的有效性。
在中国八个省份的12个城市进行了一项多中心、基于人群的前瞻性队列研究,招募年龄在40-74岁之间、无症状且无肺癌病史的个体。使用包含吸烟、身体活动水平、职业暴露、慢性呼吸道疾病史、肺癌家族史、饮食和被动吸烟(仅女性)的特定性别风险评分,将参与者分为肺癌高风险或低风险组。邀请高风险参与者进行一次性LDCT扫描,并根据他们是否进行了扫描分为筛查组和未筛查组。计算筛查组和未筛查组的肺癌发病密度、肺癌死亡率和全因死亡率。通过比较筛查组和未筛查组在队列入组至行政审查(2020年6月20日)期间的肺癌死亡率和全因死亡率,评估一次性LDCT扫描的有效性。采用逆概率加权法来考虑两组之间潜在的不平衡因素,并使用Cox比例风险模型来估计死亡率与一次性LDCT扫描之间的加权关联。
在2013年2月19日至2018年10月31日期间,评估了1032639人的资格。1016740名参与者纳入研究,其中3581人在中位随访3.6年(IQR 2.8-5.1)后被诊断为肺癌。在223302名高风险参与者中,79581人(35.6%)进行了LDCT扫描(筛查组),143721人(64.4%)未进行扫描(未筛查组)。经过逆概率加权后,与未筛查组相比,筛查组的肺癌发病密度高47.0%(风险比1.47[95%CI 1.27-1.70];p<0.0001),肺癌死亡率低31.0%(0.69[95%CI 0.53-0.92];p=0.010),全因死亡率低32.0%(0.68[0.57-0.82];p<0.0001)。
在中国的一大群人中,一次性LDCT筛查与显著降低的肺癌死亡率和全因死亡率相关。我们的结果表明一次性LDCT筛查在医疗资源有限的国家具有前景。需要进一步研究以探索按亚组(包括性别、年龄、吸烟状况和经济状况)的相互作用,以制定针对特定人群的筛查策略。
中华人民共和国财政部和国家卫生健康委员会。
摘要的中文翻译见补充材料部分。